Implant Sciences Achieves First Major Sale into Drug Detection Market

QS-B220 sale to Mexican correctional facilities represents Implant Sciences' entry into the significant international drug detection market

Jul 22, 2015, 09:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., July 22, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that, in a landmark sale for the company, it has sold 32 of its QS-B220 desktop explosives and drugs trace detectors across eight correctional facilities in Mexico. The units, which are replacing competing systems, will be deployed for drug detection.

"As informed and experienced users of trace detection, these correctional facilities chose to replace competitors' ETD systems with our QS-B220 due to Implant Sciences' expertise in non-rad ETD technology," said Dr. Darryl Jones, Vice President of Global Sales and Marketing for Implant Sciences. "Our Mexican customer was particularly impressed that our system has proven, in market after market, to deliver the highest performance and the lowest total cost of ownership and operation. We estimate that the size of the worldwide drug detection market is the range of hundreds of millions of dollars, and we are excited to have made our first sale in this arena to a country that requires high quality drug detection technology," added Dr. Jones. 

"Implant Sciences has been making significant inroads in the last year in the global aviation security market, and we are gratified to see that our value proposition and performance capabilities have now translated into other markets and applications as well," stated Dr. Bill McGann, CEO of Implant Sciences. "Our ETD systems are able to be adopted in a variety of markets and deployment scenarios to enhance security and as tools to prevent illicit contraband trafficking and criminal activity. We believe, based on the superior performance and value proposition of our product, that we will continue to expand our presence in aviation security, prisons, and border security markets, as well as in other verticals in the future."

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014).  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "believe," "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116  

SOURCE Implant Sciences Corporation